Trial
NCT04200066
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Rochester
Collaborators
—
Condition
Glioblastoma
Intervention
Temozolomide, Tamoxifen, Maprotiline
Why stopped
One of the drugs for the study is not commercially available.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-22